Gynecologic oncology最新文献

{"title":"Association of preoperative G8 score with survival, preoperative anemia and vitamin D status in gynecologic cancer patients: 5-year analysis of the Frail-B study","authors":"Valerie Catherine Linz ,&nbsp;Emma Liebau ,&nbsp;Laura Herrmann ,&nbsp;Markus Schepers ,&nbsp;Katharina Gillen ,&nbsp;Michael Mohr ,&nbsp;Mona Wanda Schmidt ,&nbsp;Marcus Schmidt ,&nbsp;Annette Hasenburg","doi":"10.1016/j.ygyno.2026.01.005","DOIUrl":"10.1016/j.ygyno.2026.01.005","url":null,"abstract":"<div><h3>Objective</h3><div>Frailty, nutritional deficiencies, and anemia frequently coexist in gynecologic cancer and may adversely influence clinical outcomes. This study aimed to evaluate the prognostic value of the G8 geriatric screening tool (G8) for survival outcomes in patients undergoing gynecologic oncology surgery, with postoperative complications and selected modifiable preoperative conditions assessed as secondary outcomes.</div></div><div><h3>Methods</h3><div>Patients ≥60 years undergoing gynecologic oncology surgery were prospectively screened for frailty between May 2020 – June 2025. Survival was evaluated with Kaplan-Meier curves and Cox regression. Propensity score matching included demographics, comorbidities, and tumor characteristics; matched samples were analyzed using weighted Cox models.</div></div><div><h3>Results</h3><div>Of 257 screened patients, 180 were included (endometrial <em>n</em> = 72, ovarian <em>n</em> = 71, vulvar <em>n</em> = 26, cervical <em>n</em> = 6, vaginal cancer <em>n</em> = 5; mean age 69.6 ± 7.9 years; follow-up 25.1 ± 16.3 months). G8 positive patients (≤14 points) had more comorbidities and were more likely to present with preoperative anemia, hypoalbuminemia, and vitamin D or B12 deficiency. FIGO stages, surgical approach and postoperative complications were comparable. G8 positive patients were less likely to receive standard adjuvant therapy (<em>p</em> = 0.003). In matched analyses, G8 positivity remained significantly associated with reduced progression-free survival (HR: 1.87, 95% CI: 1.01–3.49, <em>p</em> = 0.047) and showed a trend toward worse overall survival (HR: 2.25, 95% CI: 0.98–5.16, <em>p</em> = 0.055). Surgical resection status was the strongest predictor of oncological outcome.</div></div><div><h3>Conclusions</h3><div>A low preoperative G8 score was associated with reduced progression-free and potentially worse overall survival in older women with gynecologic tumors. The G8 may help identify modifiable factors such as anemia or vitamin D deficiency, while complete tumor resection remained the strongest prognostic factor.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 70-78"},"PeriodicalIF":4.1,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146009618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of patient-reported outcome measures for women with low health literacy in gynecologic oncology – A mixed-methods study","authors":"D.D. Seeratan ,&nbsp;A. Jongkind ,&nbsp;L.R.C.W. van Lonkhuijzen ,&nbsp;M.M. van Muilekom ,&nbsp;N.P.M. Ezendam ,&nbsp;O.C. Damman ,&nbsp;J.W.M. Aarts","doi":"10.1016/j.ygyno.2026.01.009","DOIUrl":"10.1016/j.ygyno.2026.01.009","url":null,"abstract":"<div><h3>Purpose</h3><div>Patient-reported outcome measures (PROMs) are used in oncology to assess patients' wellbeing. It is unclear if PROMs suit patients with low health literacy (HL). This study aimed to determine the prevalence of low HL in gynaecological cancer patients, describe associated clinical and sociodemographic factors, and explore PROMs use and comprehensibility for this group.</div></div><div><h3>Methods</h3><div>Patients treated for a gynaecological malignancy completed a waiting room questionnaire to assess self-perceived HL. Clinical and sociodemographic characteristics were collected via additional questions and the electronic patient file. Those with low HL, identified by the self-perceived HL screener and educational level, were interviewed, covering cognitive debriefings of a PROM-subset and semi-structured questions on attitudes toward PROMs. Patient characteristics were analyzed descriptively. Qualitative interview data were analyzed using Tourangeau's response process model and reflexive thematic analysis.</div></div><div><h3>Results</h3><div>In total, 136 patients completed the waiting room questionnaire. 23.5% (<em>n</em> = 32/136) had self-perceived low HL, of which 18 agreed to interviews. Cognitive debriefings revealed comprehensibility issues, particularly related to interpreting recall periods and response options. Some terms were perceived as ambiguous or emotionally charged. During semi-structured questions, participants expressed digital access issues and reluctance toward PROMs, often due to confusion about their purpose and absence of feedback on prior responses during consultations.</div></div><div><h3>Discussion</h3><div>Challenges with PROM comprehensibility and use among patients with low HL may hinder accurate health status reflection, impacting clinical work and research outcomes. Improvements are needed in clearly communicating PROMs' purpose and feedback on responses. To overcome comprehensibility barriers, PROMs should be developed and validated with low HL populations.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 53-62"},"PeriodicalIF":4.1,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disparities in access to gynecologic oncology visits among elderly patients with gynecologic malignancies","authors":"Clare Cutri-French ,&nbsp;Daniel H. Saris ,&nbsp;Sebastian Spataro Solorzano ,&nbsp;Xingmei Wang ,&nbsp;Colleen M. Brensinger ,&nbsp;Emily M. Ko","doi":"10.1016/j.ygyno.2026.01.010","DOIUrl":"10.1016/j.ygyno.2026.01.010","url":null,"abstract":"<div><h3>Objectives</h3><div>Despite evidence-based recommendations from SGO, ACOG, and NCCN, not all patients with gynecologic malignancies undergo consultation and management by a gynecologic oncologist. We aim to define the proportion of elderly patients with gynecologic cancers who had at least one visit with a gynecologic oncologist and evaluate for disparities in access to specialist care.</div></div><div><h3>Methods</h3><div>This is a retrospective cohort study of women with staged ovarian, uterine, and cervical cancer between 2000 and 2019 in the SEER Medicare database. Specialist visits were captured using Medicare Part B insurance claims. Descriptive statistics, <em>t</em>-tests, chi-squared tests, and univariate logistic regression were used to assess clinical and socioeconomic factors associated with in-person visits.</div></div><div><h3>Results</h3><div>15,249 ovarian, 27,586 uterine, and 2647 cervical cancer patients were included in this study. There was an increase in the proportion of patients who saw gynecologic oncologists over time. Overall, 54.35% of ovarian, 61.49% of uterine, and 62.14% of cervical cancer patients saw a gynecologic oncologist for at least one visit. Those who were younger, living in census tracks with higher median income, and living in the Northeast were more likely to see a gynecologic oncologist. Visit access also varied by stage. Black and Hispanic patients with uterine cancer were more likely to see a gynecologic oncologist.</div></div><div><h3>Conclusions</h3><div>Less than two thirds of elderly patients with newly diagnosed gynecologic malignancies had a visit with a gynecologic oncologist. There were differences in access based on age, stage, geographic region, census track-based median income, and year of diagnosis in all subgroups.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 63-69"},"PeriodicalIF":4.1,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends, predictors, and safety of ovarian preservation in premenopausal women with high-grade endometrioid and non-endometrioid endometrial cancers","authors":"Jaida E. Morgan ,&nbsp;Ling Chen ,&nbsp;Xiao Xu ,&nbsp;Shayan Dioun ,&nbsp;Alexander Buckley ,&nbsp;Thomas Randall ,&nbsp;Tarah Pua ,&nbsp;Caryn M. St. Clair ,&nbsp;June Y. Hou ,&nbsp;Koji Matsuo ,&nbsp;Dawn L. Hershman ,&nbsp;Jason D. Wright","doi":"10.1016/j.ygyno.2026.01.004","DOIUrl":"10.1016/j.ygyno.2026.01.004","url":null,"abstract":"<div><h3>Objective</h3><div>While ovarian preservation has been shown to be safe for premenopausal patients with low-grade, early-stage endometrioid endometrial cancer, there is limited data for higher risk tumors. We assessed the trends, predictors, and survival associated with ovarian preservation at the time of hysterectomy among premenopausal women with high-risk, early-stage endometrial cancers.</div></div><div><h3>Methods</h3><div>Women &lt;50 years of age with stage I-II grade 2 endometrioid or high-risk (grade 3 endometrioid, non-endometrioid) endometrial cancers diagnosed from 2012 to 2022 and recorded in the National Cancer Database (NCDB) were examined. A multivariable logistic regression model, was used to examine factors associated with ovarian preservation. Adjusted survival curves and a Cox proportional hazards model (with inverse probability of treatment weighting [IPTW]) were used to compare the hazards of survvial in women who did and did not undergo ovarian preservation.</div></div><div><h3>Results</h3><div>A total of 7230 women including 295 (4.1 %) who underwent ovarian preservation were identified. The rate of ovarian preservation declined over time. Older age was associated with lower odds of ovarian preservation. After IPTW, 5-year survival was 94.2 % (95 % CI: 90.2–96.6 %) with ovarian preservation and 94.4 % (95 % CI: 93.5–95.2 %) with oophorectomy. In the weighted Cox proportional hazards model, ovarian preservation was not associated with overall survival (HR = 1.05, 95 % CI = 0.57–1.94).</div></div><div><h3>Conclusions</h3><div>Use of ovarian preservation in premenopausal women with high-risk endometrial cancers has decreased over time. Ovarian preservation was not associated with an adverse impact on survival.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 46-52"},"PeriodicalIF":4.1,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145973556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial","authors":"Se Ik Kim ,&nbsp;Jae-Weon Kim ,&nbsp;Janice S. Kwon ,&nbsp;Sarah E. Ferguson ,&nbsp;Alexandra Sebastianelli ,&nbsp;Paul Bessette ,&nbsp;Sven Mahner ,&nbsp;Tristan Gauthier ,&nbsp;Cor de Kroon ,&nbsp;Willemien van Driel ,&nbsp;Karin Williamson ,&nbsp;Frederic Goffin ,&nbsp;Stephan Polterauer ,&nbsp;Brynhildur Eyjólfsdóttir ,&nbsp;Jung-Yun Lee ,&nbsp;Patrick J. Maguire ,&nbsp;Ingolf Juhasz-Böss ,&nbsp;Hyunji Lim ,&nbsp;Aeran Seol ,&nbsp;Lois Shepherd ,&nbsp;Marie Plante","doi":"10.1016/j.ygyno.2026.01.001","DOIUrl":"10.1016/j.ygyno.2026.01.001","url":null,"abstract":"<div><h3>Objective</h3><div>To compare oncologic outcomes and perioperative morbidity between simple hysterectomy (SH) and radical hysterectomy (RH) in patients with and without very low-risk early-stage cervical cancer from the phase III Simple Hysterectomy And PElvic node assessment (SHAPE) trial.</div></div><div><h3>Methods</h3><div>Patients who underwent SH or RH in the SHAPE trial were classified into the Conservative SHAPE group (very low-risk), meeting criteria similar to the ConCerv trial, and the Liberal SHAPE group (without very low-risk), including everyone else. Between the SH and RH arms in each group, survival outcomes, including recurrence-free survival (RFS) and overall survival (OS), and intraoperative and postoperative morbidities were compared. Factors associated with recurrence and mortality rates were also investigated.</div></div><div><h3>Results</h3><div>In the Conservative SHAPE group (<em>n</em> = 107), no recurrence was observed in either SH or RH arms, and only one non-cancer-related death in the RH arm during a median follow-up of 4.5 years. In the Liberal SHAPE group (<em>n</em> = 575), the SH arm showed similar 3-year pelvic RFS (96.9 % vs. 97.4 %; HR, 1.15; 95 % CI, 0.49–2.70), extrapelvic RFS (97.7 % vs. 99.6 %; HR, 3.64; 95 % CI, 0.76–17.5), overall RFS (95.4 % vs. 97.4 %; HR, 1.56; 95 % CI, 0.70–3.48), and OS (98.9 % vs. 99.3 %; HR, 1.21; 95 % CI, 0.41–3.59), compared with the RH arm. In multivariate analyses, SH was not associated with recurrence and mortality rates, while absence of residual disease in the hysterectomy specimen was associated with lower recurrence. In both groups, SH was associated with a lower risk of urinary retention and incontinence.</div></div><div><h3>Conclusion</h3><div>There were similar recurrence and survival outcomes but less morbidity from simple hysterectomy compared to radical hysterectomy in patients with and without very low-risk early-stage cervical cancer from the SHAPE trial.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 37-45"},"PeriodicalIF":4.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of a mobile health platform for patient education and remote symptom monitoring in patients with advanced ovarian cancer undergoing primary chemotherapy1","authors":"Haller J. Smith ,&nbsp;Kaitlyn Dinkins ,&nbsp;Margaret I. Liang ,&nbsp;Daniel I. Chu ,&nbsp;Warner K. Huh","doi":"10.1016/j.ygyno.2025.12.006","DOIUrl":"10.1016/j.ygyno.2025.12.006","url":null,"abstract":"<div><h3>Objective</h3><div>To design and implement a mobile health (mHealth) patient engagement platform for use in patients with advanced ovarian cancer undergoing primary chemotherapy.</div></div><div><h3>Methods</h3><div>This prospective pilot study included patients with newly diagnosed epithelial ovarian cancer undergoing primary chemotherapy at a single institution from 8/2021–11/2023. Patients were offered enrollment in a mHealth platform which provided access to an education library and sent weekly health checks for the duration of their chemotherapy. Mild symptoms triggered recommendations for care at home, while more severe symptoms prompted a call or alert to the care team. The primary outcome was feasibility of the intervention. Secondary outcomes included frequency and severity of symptoms reported, recommended interventions, and patient reported outcomes (PROs).</div></div><div><h3>Results</h3><div>44 patients were enrolled during the study period. Activation rate was 79.5 %. Of the patients who activated, adherence was high with 77.1 % of patients still active at 3 months. Mean number of health checks completed was 16.1 (range 1–50). Commonly reported symptoms were fatigue (26.4 %), joint pain (24.2 %), neuropathy (22.2 %), and abdominal pain (18.7 %). Of 578 total health checks, 60.2 % triggered additional education, 20.9 % prompted a call to the care team, and 9.9 % resulted in an automated alert. 94 % of patients completed at least one PRO survey.</div></div><div><h3>Conclusions</h3><div>This mHealth intervention was feasible in patients with advanced ovarian cancer undergoing primary chemotherapy and was associated with high adherence. mHealth interventions may help better identify adverse effects in patients undergoing chemotherapy and provide earlier opportunities for intervention compared to standard in-person visits.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 27-31"},"PeriodicalIF":4.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging tumor multigene panel testing to identify germline variants in gynecologic cancers: A retrospective evaluation of an algorithm-based approach","authors":"Maitreyee Parulekar ,&nbsp;Yoo-Na Kim ,&nbsp;Kidong Kim ,&nbsp;Sejoon Lee ,&nbsp;Jae Hong No ,&nbsp;Jung-Yun Lee ,&nbsp;Yong Beom Kim","doi":"10.1016/j.ygyno.2026.01.003","DOIUrl":"10.1016/j.ygyno.2026.01.003","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the recall rate and positive predictive value of a novel algorithm for recommending germline testing in women with variants identified through tumor gene panel testing.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed in patients with gynecological cancers who underwent TruSight Oncology 500 tumor gene panel testing (Illumina, San Diego, CA, USA) between September 2020 and July 2023 at two tertiary institutions in Korea. The algorithm recommends germline testing for patients who meet the following criteria: (1) presence of Tier 1 or 2 variants in any of 11 oncogenes (<em>BRCA1</em>, <em>BRCA2</em>, <em>PALB2</em>, <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, <em>BRIP1</em>, <em>RAD51C</em>, <em>RAD51D</em>, <em>ATM</em>, and <em>CHEK2</em>) with a variant allele frequency (VAF) of ≥40 %; and (2) exclusion of epithelial ovarian cancers with <em>BRCA</em> variants. Medical records were reviewed to assess germline testing results and their concordance with the somatic findings.</div></div><div><h3>Results</h3><div>The algorithm recommended germline testing for 19 of the 702 patients (recall rate: 2.7 %). Of these, four patients underwent germline testing based on tumor-detected variants. All four patients were confirmed to have germline variants identical to their somatic findings (positive predictive value: 100 %). Specifically, germline mutations were confirmed in one endometrial cancer (endometroid) patient with a <em>BRCA</em> variant, one tubo-ovarian cancer (high grade serous) patient with a <em>RAD51D</em> variant, and two tubo-ovarian cancers (high grade serous) patients with <em>BRIP1</em> variants.</div></div><div><h3>Conclusion</h3><div>A conservative (specificity-focused) tumor-guided algorithm demonstrated high positive predictive value for identifying germline pathogenic variants and may provide a cost-effective means of prioritizing genetic counselling and germline testing in resource-limited settings.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 32-36"},"PeriodicalIF":4.1,"publicationDate":"2026-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer","authors":"Wenjie Tang ,&nbsp;Lu Wang ,&nbsp;Xiaolin Li ,&nbsp;Xiaohui Yan ,&nbsp;Qiufen Guo ,&nbsp;Qian Wu ,&nbsp;Chunhui Cui ,&nbsp;Bowen Liu ,&nbsp;Jianbo Zhang ,&nbsp;Lu Zhang ,&nbsp;Xueliang Zhang ,&nbsp;Dapeng Li ,&nbsp;Peng Xie","doi":"10.1016/j.ygyno.2025.12.007","DOIUrl":"10.1016/j.ygyno.2025.12.007","url":null,"abstract":"<div><h3>Objective</h3><div>Although widely used for immune checkpoint inhibitors (ICIs) therapy patient selection, programmed death-ligand 1 (PD-L1) remains an imperfect biomarker for such selection. We explored the impact of radiotherapy (RT) on PD-L1 and the tumor microenvironment (TME) and delved into the mechanisms underlying this effect in cervical cancer.</div></div><div><h3>Methods</h3><div>Patients with treatment-naïve cervical cancer who underwent RT between March 2021 and October 2022 were included. Cancer tissue samples were collected during RT. PD-L1 expression was evaluated by immunohistochemical staining. Lymphocytes in the TME were detected by multiplex immunofluorescence (mIF). SiHa, CaSki, U14, and TC-1 cells verified the in vitro findings using western blot analysis.</div></div><div><h3>Results</h3><div>Among the 40 cases, although the expression changed constantly, PD-L1 was significantly upregulated in most patients exposed to doses of 10–14 and 18–22 Gy; this radiation-induced acquired PD-L1 expression was consistently observed regardless of patients' baseline PD-L1 status or concurrent chemotherapy. In vitro experiments confirmed increased PD-L1 post-RT. RNA sequencing revealed NF-κB signaling pathway enrichment in the CD274-elevated group. Western blotting indicated significant p-P65 and p-IKKα/β increases post-irradiation; PD-L1 decreased with NF-κB activation inhibitors. mIF demonstrated increased CD8⁺ T cell and macrophage infiltration into tumor nests (<em>P</em> = 0.0496; <em>P</em> = 0.0017) and tumor stroma (<em>P</em> = 0.0049), with overall increased TME infiltration (<em>P</em> = 0.0139; <em>P</em> = 0.0321).</div></div><div><h3>Conclusion</h3><div>RT induces PD-L1 expression and enhances CD8⁺ T cell and macrophage infiltration into the TME of patients with cervical cancer. Therefore, it may establish an immunologically favorable context for synergistic action with subsequent immunotherapy.</div></div>","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"205 ","pages":"Pages 17-26"},"PeriodicalIF":4.1,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer","authors":"Christina M. Annunziata","doi":"10.1016/j.ygyno.2025.12.011","DOIUrl":"10.1016/j.ygyno.2025.12.011","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages A1-A2"},"PeriodicalIF":4.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOC","authors":"","doi":"10.1016/S0090-8258(25)01148-5","DOIUrl":"10.1016/S0090-8258(25)01148-5","url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":"204 ","pages":"Pages iv-vi"},"PeriodicalIF":4.1,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145921180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}